Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

Pfizer

Status: Completed

Conditions: EGFR Mutation-positive Inoperable or Reccrent NSCLC

Treatments: Drug: dacomitinib hydrate

Study type: Observational

Funder types: Industry

Identifiers

NCT04155541

A7471048

Details and patient eligibility

About

Secondary data collection study: safety and efficacy of VIZIMPRO under Japanese medical practice

Enrollment: 40 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• patient with EGFR mutation-positive inoprable or recurrent NSCLC who have not received VIZIMPRO(dacomitinib hydrate)

Exclusion criteria

• Exclusion criteria is not provided in this study

Trial design

40 participants in 1 patient group

VIZIMPRO(dacomitinib hydrate)

Description:

Patients with EGFR mutation-positive inoperable or recorrent NSCLN (non-small cell lung cancer) who have not received VIZIMPRO (dacomitinib hydrate)

Treatment:

Drug: dacomitinib hydrate